Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	25.13	31.63	18.53	19.13	19.99	5.74
Cash & Short-Term Investments	25.13	31.63	18.53	19.13	19.99	5.74
Cash Growth	-15.85%	70.69%	-3.10%	-4.34%	248.19%	-
Other Current Assets	0.27	0.08	0.07	0.06	0.41	0.92
Total Current Assets	25.4	31.71	18.61	19.19	20.41	5.83
Total Assets	25.4	31.71	18.61	19.19	20.41	6.66
Accounts Payable	4.7	6.27	2.5	2.77	2.91	1.06
Accrued Expenses	6.48	7.02	6.4	4.21	2.83	0.54
Other Current Liabilities	-	-	-	-	0.45	0.82
Total Current Liabilities	11.18	13.3	8.89	6.98	6.19	2.42
Total Liabilities	11.18	13.3	8.89	6.98	6.19	2.42
Additional Paid-in Capital	119.96	118.1	82.96	66.45	46.2	1.89
Retained Earnings	-105.74	-99.69	-73.25	-54.25	-31.99	-12.9
Total Common Shareholders' Equity	14.22	18.41	9.71	12.2	14.22	-11.01
Minority Interest	-	-	-	-	-	15.25
Shareholders' Equity	14.22	18.41	9.71	12.2	14.22	4.24
Total Liabilities & Equity	25.4	31.71	18.61	19.19	20.41	6.66
Net Cash (Debt)	25.13	31.63	18.53	19.13	19.99	5.74
Net Cash Growth	-20.56%	70.69%	-3.10%	-4.34%	248.19%	-
Net Cash Per Share	1.11	1.45	1.08	1.23	1.58	1.34
Book Value	14.22	18.41	9.71	12.2	14.22	-11.01
Book Value Per Share	0.63	0.84	0.57	0.78	1.12	-2.58
Tangible Book Value	14.22	18.41	9.71	12.2	14.22	-11.01
Tangible Book Value Per Share	0.63	0.84	0.57	0.78	1.12	-2.58

SEC Filings: 10-K · 10-Q